NEW YORK — Eli Lilly is preparing its Food and Drug Administration application for retatrutide, a next-generation weight-loss drug. Phase 3 trial data showed the treatment delivered substantial weight reduction across multiple patient cohorts, and the formal submission extends Lilly's lead in the obesity pharmaceutical market.
Retatrutide acts on three gut hormones—GLP-1, GIP and glucagon—offering a broader mechanism than existing GLP-1 agonists. Clinical trials showed patients achieved average weight loss exceeding 24 percent over 48 weeks at higher doses, outperforming Zepbound and setting a new efficacy benchmark in a competitive field.
Lilly already leads the weight-loss market with Zepbound for obesity and Mounjaro for Type 2 diabetes, both GLP-1/GIP receptor agonists. Demand continues to outstrip supply, driving strong revenue growth across the existing portfolio. BMO Capital Markets projects retatrutide could generate over $25 billion in annual peak sales by 2032, contributing to a global weight-loss drug market forecast to surpass $100 billion. That forecast assumes rapid market adoption and favorable reimbursement.
The FDA submission is a key catalyst for Lilly shares. Novo Nordisk competes aggressively with Wegovy and its own pipeline, but retatrutide's efficacy profile positions Lilly strongly. JPMorgan reiterated its Overweight rating on Lilly and raised its 12-month price target to $1,200, reflecting the drug's potential to widen Lilly's lead in obesity despite rising research and development costs.
Scaling manufacturing to meet anticipated demand will be a major operational challenge, mirroring difficulties Lilly faced with Zepbound production. The company's investment in expanding production capacity and its deep pipeline of metabolic drugs support its leadership as the obesity market matures and diversifies.
